BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

Author: Merck / 2023-07-23 22:07 / Source: Merck

BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

Not intended for US-,Canada- and UK-based media

DARMSTADT,Germany,and NEW YORK,Sept. 18,2020 --Merck and Pfizer Inc. (NYSE: PFE) today announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine. These results were published simultaneously with additional analyses being presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and describe the efficacy of BAVENCIO®(avelumab) as a first-line maintenance treatment across various subgroups of patients with locally advanced or metastatic urothelial carcinoma (UC) and highlight exploratory biomarkers as well as patient-reported outcomes. In June,the US Food and Drug Administration (FDA) approved BAVENCIO for the maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy based on the JAVELIN Bladder 100 results.

In the JAVELIN Bladder 100 study,BAVENCIO plus best supportive care (BSC) significantly extended overall survival (OS) compared with BSC alone in the two primary populations of all randomized patients and patients whose tumors were PD-L1+,and significantly more patients who received BAVENCIO as first-line maintenance were alive at one year.[1] The clinical benefits of BAVENCIO were seen across a range of patient populations.[1],[2]

"These data,which supported the recent FDA approval and updates to NCCN and ESMO guidelines,establish that BAVENCIO first-line maintenance treatment could fundamentally change clinical practice for the treatment of patients with locally advanced or metastatic urothelial carcinoma," said Thomas Powles,MBBS,MRCP,MD,Professor of Genitourinary Oncology,Lead for Solid Tumour Research at Barts Cancer Institute,Queen Mary University of London,and Director of Barts Cancer Centre,London,UK. "It is notable that the longer overall survival with BAVENCIO maintenance therapy was observed across all pre-specified subgroups examined and that this prolonged overall survival was gained without a detrimental impact on patients' quality of life."

Primary Analysis

In the JAVELIN Bladder 100 study,OS was significantly longer with BAVENCIO plus BSC compared to BSC alone in the primary population of all randomized patients (n=700) whose disease had not progressed on first-line platinum-containing chemotherapy:

Median OS was 21.4 months (95% CI,18.9 to 26.1) vs 14.3 months (95% CI,12.9 to 17.9),respectively (HR 0.69; 95% CI,0.56 to 0.86; P<0.001).[1]

At one year,71.3% of patients (95% CI,66.0% to 76.0%) in the BAVENCIO arm were alive vs 58.4% (95% CI,52.7% to 63.7%) of patients who received BSC alone.[1]

In the other primary population of patients with PD-L1+ tumors (n=358):

OS was also significantly longer with BAVENCIO plus BSC vs BSC alone (HR 0.56; 95% CI,0.40 to 0.79; P<0.001).[1]

At one year,79.1% (95% CI,72.1% to 84.5%) of patients who received BAVENCIO were alive vs 60.4% (95% CI,52.0% to 67.7%) in the BSC arm.[1]

All endpoints were measured from the time of randomization,after completion of four to six cycles of chemotherapy.

Subgroup Analysis

Results of an exploratory subgroup analysis show that consistent results were observed with the JAVELIN Bladder regimen of BAVENCIO first-line maintenance across pre-specified subgroups,including best response to first-line chemotherapy,type of chemotherapy regimen,site of baseline metastasis,and other baseline factors.[1] In particular,hazard ratios for OS based on response to first-line chemotherapy were as follows:

0.69 for complete or partial response

0.70 for stable disease

With regard to first-line chemotherapy regimen,hazard ratios were as follows:

0.69 with gemcitabine plus cisplatin

0.66 with gemcitabine plus carboplatin

Further detail from the subgroup analysis were presented in an on-demand mini oral session at the meeting (Presentation #704MO). Additional data evaluating the association between clinical outcomes and exploratory biomarkers will be presented in the Proffered Paper 1 - GU,non prostate session on Saturday,September 19 (Presentation #699O),and patient-reported outcomes are featured in an on-demand e-poster display (Presentation #745P).

Safety

No new safety signals were identified in the JAVELIN Bladder 100 study,and the safety profile was consistent with previous studies of BAVENCIO monotherapy.[1] Treatment-related adverse events of grade 3 or higher occurred in 57 patients (16.6%) treated with BAVENCIO plus BSC; no grade 3 or higher treatment-related events occurred in the control arm.[1] No grade 4 or fatal immune-related adverse events occurred.[1] Investigators attributed two patient deaths in the BAVENCIO plus BSC arm (0.6%),due to sepsis and ischemic stroke,to study treatment toxicity.[1]

About JAVELIN Bladder 100

JAVELIN Bladder 100 (NCT02603432) is a Phase III,multicenter,multinational,randomized,open-label,parallel-arm study investigating first-line maintenance treatment with BAVENCIO plus BSC versus BSC alone in patients with locally advanced or metastatic UC. The primary endpoint was OS in the two primary populations of all patients and patients with PD-L1+ tumors defined by the Ventana SP263 assay. Secondary endpoints included progression-free survival,anti-tumor activity,safety,pharmacokinetics,immunogenicity,predictive biomarkers and patient-reported outcomes in the co-primary populations. All primary and secondary endpoints are measured from the time of randomization.

About Urothelial Carcinoma

Bladder cancer is the tenth most common cancer worldwide.[4] In 2018,there were over half a million new cases of bladder cancer diagnosed,with around 200,000 deaths from the disease globally.[4] In the US,an estimated 80,470 cases of bladder cancer were diagnosed in 2019,with around 12,500 locally advanced or metastatic cases presented annually.[5],[6] UC,which accounts for about 90% of all bladder cancers,[7] becomes harder to treat as it advances,spreading through the layers of the bladder wall.[8] Only 25% to 55% of patients receive any second-line therapy after first-line chemotherapy.[9-15]In the US and EU5 markets,approximately 40% to 50% of patients receive an immune checkpoint inhibitor in second-line therapy.[3]For patients with advanced UC,the five-year survival rate is 5%.[5]

About BAVENCIO® (avelumab)

BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors,BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.[16-18] In November 2014,Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize BAVENCIO.

BAVENCIO Approved Indications

The European Commission (EC) has authorized the use of BAVENCIO in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). BAVENCIO is also authorized by the EC for use as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).

In the US,BAVENCIO is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. BAVENCIO is also indicated for the treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy,or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

BAVENCIO in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced RCC. Additionally,the US Food and Drug Administration (FDA) granted accelerated approval for BAVENCIO for the treatment of adults and pediatric patients 12 years and older with metastatic MCC. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

BAVENCIOis currently approved for patients with MCC in 50 countries globally,with the majority of these approvals in a broad indication that is not limited to a specific line of treatment.

BAVENCIO Safety Profilefrom the EU Summary of Product Characteristics (SmPC)

The special warnings and precautions for use for BAVENCIO monotherapy include infusion-related reactions,as well as immune-related adverse reactions that include pneumonitis and hepatitis (including fatal cases),colitis,pancreatitis (including fatal cases),myocarditis (including fatal cases),endocrinopathies,nephritis and renal dysfunction,and other immune-related adverse reactions. The special warnings and precautions for use for BAVENCIO in combination with axitinib include hepatotoxicity.

The SmPC list of the most common adverse reactions with BAVENCIO monotherapy in patients with solid tumors includes fatigue,nausea,diarrhea,decreased appetite,constipation,infusion-related reactions,weight decreased and vomiting. The list of most common adverse reactions with BAVENCIO in combination with axitinib includes diarrhea,hypertension,fatigue,dysphonia,hypothyroidism,cough,headache,dyspnea,and arthralgia.

About Merck-Pfizer Alliance

Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other's strengths and capabilities and further explore the therapeutic potential of BAVENCIO,an anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance is jointly developing and commercializing BAVENCIO. The alliance is focused on developing high-priority international clinical programs to investigate BAVENCIO as a monotherapy as well as combination regimens,and is striving to find new ways to treat cancer.

All Merck Press Releasesare distributed by e-mail at the same time they become available on the MerckWebsite. Pleasego to www.merckgroup.com/subscribeto register online,change your selection or discontinue this service.

About Merck

Merck,a leading science and technology company,operates across healthcare,life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019,Merck generated sales of € 16.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada,where the business sectors of Merck operate as EMD Serono in healthcare,MilliporeSigma in life science,and EMD Performance Materials.

Pfizer Inc.: Breakthroughs that change patients' lives

At Pfizer,we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality,safety and value in the discovery,development and manufacture of health care products,including innovative medicines and vaccines. Every day,Pfizer colleagues work across developed and emerging markets to advance wellness,prevention,treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies,we collaborate with health care providers,governments and local communities to support and expand access to reliable,affordable health care around the world. For more than 150 years,we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com.In addition,to learn more,please visit us on www.pfizer.comand follow us on Twitter at @Pfizerand @Pfizer_News,LinkedIn,YouTubeand like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information contained in this release is as of September 18,2020. Pfizer assumes no obligation to update forward-looking statementscontained in this release as the result of new information or future events or developments.

This release contains forward-looking information about BAVENCIO (avelumab),including an indication for first-line maintenance therapy for BAVENCIO for the treatment of patients with locally advanced or metastatic urothelial carcinoma,the alliance between Merck and Pfizer involving BAVENCIO and clinical development plans,including their potential benefits,that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include,among other things,uncertainties regarding the commercial success of BAVENCIO; the uncertainties inherent in research and development,including the ability to meet anticipated clinical endpoints,commencement and/or completion dates for our clinical trials,regulatory submission dates,regulatory approval dates and/or launch dates,as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and whenany drug applications may be filed in any other jurisdictions for BAVENCIO for first-line maintenance therapy for locally advanced or metastatic urothelial carcinoma in any jurisdictions or for any other potential indications for BAVENCIO or combination therapies in any jurisdictions; whether and when regulatory authorities in any jurisdictions where any applications are pending or may be submitted for BAVENCIO or combination therapies,including BAVENCIO for locally advanced or metastatic urothelial carcinoma may approve any such applications,which will depend on myriad factors,including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy,and,if approved,whether they will be commercially successful; decisions by regulatory authorities impacting labeling,manufacturing processes,safety and/or other matters that could affect the availability or commercial potential of BAVENCIO,including BAVENCIO for locally advanced or metastatic urothelial carcinoma; the impact of COVID-19 on our business,operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31,2019,and in its subsequent reports on Form 10-Q,including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results",as well as in its subsequent reports on Form 8-K,all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

References

Powles T,Park SH,Voog E,et al. Avelumab maintenance therapy for advanced or metastatic urothelial cancer. N Engl J Med. 2020. [Epub ahead of print]. DOI: 10.1056/NEJMoa2002788.

Grivas P,Park SE,et al. Avelumab 1L maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy for advanced urothelial carcinoma: subgroup analyses from JAVELIN Bladder 100. Presented at ESMO 2020.

Kantar Health. CANCERMPACT – treatment architecture.https://www.kantarhealth.com/docs/datasheets/cancermpact-treatment-architecture.pdf?sfvrsn=6&sfvrsn=6. Accessed September 2020.

Bray F,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal. 2018;68(6):394-424.

SEER. Cancer stat facts: bladder cancer. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed September 2020.

Galsky M,et al. Cisplatin ineligibility for patients with metastatic urothelial carcinoma: a survey of clinical practice perspectives among US oncologists. Bladder Cancer. 2019;5:281-288.

Cancer.net.Bladder cancer: introduction. https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed September 2020.

American Cancer Society. What is bladder cancer? https://www.cancer.org/cancer/bladder-cancer/about/what-is-bladder-cancer.html. Accessed September 2020.

Cheeseman S,et al. Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer from a large UK-based single centre. Front Oncol. 2020;10:167.

Aly A,et al. Overall survival,costs,and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma. J Med Econ. 2019;22:662-670.

Galsky MD,et al. Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States. Bladder Cancer. 2018;4(2):227-238.

Fisher MD,et al. Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008-2015. Clin Genitourin Cancer. 2018;16:e1171-e1179.

Niegisch G,et al. A real-world data study to evaluate treatment patterns,clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany. J Cancer. 2018;9(8):1337-1348.

Flannery K,et al. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. Future Oncol. 2019;15:1323-1334.

Simeone JC,et al. Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world,US setting. Cancer Epidemiol. 2019;60:121-127.

Dolan DE,Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014;21(3):231-237.

Dahan R,Sega E,Engelhardt J,et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 2015;28(3):285-295.

Boyerinas B,Jochems C,Fantini M,et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148-1157.

Your Contacts

Merck

Media Relations

+49 6151 72-9591

gangolf.schrimpf@merckgroup.com

Investor Relations

+49 6151 72-3321

investor.relations@merckgroup.com

Pfizer Inc.,New York,USA

Media

Dervila Keane (EU)

+ 353 86 2110834